/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Journal of Clinical Oncology (JCO) Podcast
  2. Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC
Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast · Aug 13, 2026

The BART trial shows adjuvant radiotherapy significantly improves locoregional control for high-risk MIBC post-cystectomy, a key local solution.

In Post-Cystectomy Bladder Cancer, Locoregional Relapse Is as Lethal as Distant Metastasis

Data from the BART trial revealed that post-operative patients who experienced a locoregional relapse had a median survival of only 6.5-7 months. This grim prognosis was surprisingly identical to that of patients with distant metastasis, underscoring the critical importance of preventing local disease recurrence.

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC thumbnail

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast·3 months ago

Modern IMRT Safely Delivers Post-Cystectomy Radiation, Mitigating Bowel Toxicity Fears

Despite initial concerns about irradiating the post-cystectomy bed due to bowel proximity, the BART trial demonstrated that using strict Intensity-Modulated Radiation Therapy (IMRT) makes the procedure safe. This approach resulted in only 17-20% grade two acute side effects, a reasonable trade-off for the clinical benefit.

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC thumbnail

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast·3 months ago

Irradiating the Entire Cystectomy Bed Is Critical, Regardless of Surgical Margins

A key debate in designing the BART trial was whether to irradiate the cystectomy bed only for margin-positive patients. The trial's protocol mandated including the bed for all patients. Subsequent data has validated this decision, showing the entire bed is at risk for recurrence, a crucial finding for radiation field design.

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC thumbnail

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast·3 months ago

Adjuvant Radiotherapy and Immunotherapy in Bladder Cancer Likely Offer Non-Overlapping Benefits

The BART trial investigator posits that adjuvant radiotherapy's role in locoregional control is distinct from immunotherapy's systemic effect. Since their side effect profiles don't overlap, there is a strong rationale for combining these modalities to improve both local and distant control, even without direct comparative data yet.

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC thumbnail

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast·3 months ago

Locoregional Relapse in Advanced Bladder Cancer is an Underdiagnosed and Underappreciated Problem

The rationale for the BART trial was the premise that locoregional relapses after cystectomy are a significant and often overlooked issue. While distant metastases get more attention, a substantial portion of treatment failures are local, causing significant morbidity and contributing to the 40% mortality rate at 2-3 years.

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC thumbnail

Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC

Journal of Clinical Oncology (JCO) Podcast·3 months ago